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Objectives: To compare the short-term mortality rates of gastrointestinal (GI) bleeding to 
those of acute myocardial infarction (AMI) by estimating the 30-, 60-, and 90-day mortality 
among hospitalized patients.
Methods: United States national health plan claims data (1999–2003) were used to identify 
patients hospitalized with a GI bleeding event. Patients were propensity-matched to AMI patients 
with no evidence of GI bleed from the same US health plan.
Results: 12,437 upper GI-bleed patients and 22,847 AMI patients were identiﬁ  ed. Propensity 
score matching yielded 6,923 matched pairs. Matched cohorts were found to have a similar 
Charlson Comorbidity Index score and to be similar on nearly all utilization and cost measures 
(excepting emergency room costs). A comparison of outcomes among the matched cohorts 
found that AMI patients had higher rates of 30-day mortality (4.35% vs 2.54%; p  0.0001) 
and rehospitalization (2.56% vs 1.79%; p = 0.002), while GI bleed patients were more likely to 
have a repeat procedure (72.38% vs 44.95%; p  0.001) following their initial hospitalization. 
The majority of the difference in overall 30-day mortality between GI bleed and AMI patients 
was accounted for by mortality during the initial hospitalization (1.91% vs 3.58%).
Conclusions: GI bleeding events result in signiﬁ  cant mortality similar to that of an AMI after 
adjusting for the initial hospitalization.
Keywords: gastrointestinal, bleeding, mortality, acute myocardial infarction, claims analysis
Introduction
Upper gastrointestinal (GI) bleeding is a common medical condition that may lead 
to substantial morbidity and mortality. The incidence rate of GI bleeding events has 
varied substantially in the published literature, in part due to the broad deﬁ  nitions used 
to examine GI bleeds. One systematic review of 40 publications of serious upper GI 
bleeds, perforations, and other complications found an incidence rate of one per 1,000 
person-years among nonusers of prescription nonsteroidal anti-inﬂ  ammatory drugs 
(NSAIDs).1 A recently published retrospective claims data study found an incidence 
rate of GI bleeding events among NSAID users of 18 per 1,000 person-years.2 Other 
studies report the incidence of acute upper GI bleed at approximately one case per 1,000 
adults in the general population each year.3,4 GI bleeding results in 250,000 to 300,000 
hospitalizations and 15,000 to 30,000 deaths per year in the United States.5,6 Some 
studies point to a 30-day mortality rate due to GI bleeding events as high as 14%,7,8 while 
others report a range between 6% and 10% per year, with rates increasing in patients Clinical and Experimental Gastroenterology 2009:2 22
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with advancing age and increasing number of associated 
underlying comorbidities.9–11 More than $2.5 billion is spent 
annually for inpatient care of this problem.6
Along with malignant neoplasms, cerebrovascular dis-
eases, and chronic lower respiratory diseases, acute myo-
cardial infarction (AMI) belongs to a category of disease 
(diseases of the heart) associated with the greatest mortality 
and morbidity.12 AMI was chosen as a comparison because 
it is easily recognized by physicians as a cause of mortality. 
Unlike mortality caused by GI bleeds, the degree of mortality 
associated with AMI has been better documented. AMI is a 
medical emergency, and the leading cause of death for both 
men and women worldwide.13 It is estimated that 1,200,000 
people suffer a (new or recurrent) coronary attack every year. 
Thirty-day risk-standardized mortality from AMI among 
patients aged 30–64 is reported as 7%, while among patients 
aged 65 years or older, a 15.9% to 23.5% risk was recently 
reported.14–16 In 2004, MI resulted in 732,000 to 896,000 
hospitalizations in the United States (US). The estimated 
total (direct and indirect) cost of coronary heart disease in 
the US for 2007 is $151.6 billion.13
Despite the high mortality rate of GI bleeding events and 
the well known factors associated with the risk of bleeds, 
more research is required to assess mortality rates of GI 
bleeding events. Published US mortality data is outdated with 
no new studies evaluating GI mortality published after the 
year 2000. Understanding how mortality among patient with 
GI bleeding events compares to the mortality associated with 
an AMI may be valuable in providing context for assessing 
the impact of the costs and consequences of GI bleeding 
among patients enrolled in a large managed care organization. 
The main objective of this study was to examine the 30-, 60-, 
and 90-day mortality among patients hospitalized for upper 
GI bleeds compared to a propensity-matched control cohort 
of patients with acute AMI.
Methods
Data source
This was a retrospective cohort analysis using medical and 
pharmacy claims data and enrollment information from a 
large managed health care plan in the United States. Claims 
are submitted by physicians, facilities, and pharmacies 
for payment of services provided to covered health plan 
members. The administrative claims database included data 
for approximately 14 million covered lives with both medical 
and pharmacy beneﬁ  ts. The health plan comprises discounted 
fee-for-service independent practice association plans span-
ning the US, with the largest concentration in the southern 
and midwestern regions. All study data were de-identiﬁ  ed and 
accessed with protocols compliant with the Health Insurance 
Portability and Accountability Act.
GI bleeding study subject identiﬁ  cation
Patients at least 18 years of age with evidence of a hospi-
talization for an upper GI bleeding event during the period 
from January 1st, 2000 through December 31st, 2003 
were identiﬁ  ed from the claims data and were selected for 
inclusion if they had not been hospitalized for GI bleeding 
or for GI surgery in the six-month pre-index period and 
had no evidence of a hospitalization for AMI in the six-
month pre-index period. The admission date of the ﬁ  rst 
occurring hospitalization for a GI bleeding event, without 
evidence of trauma, was deﬁ  ned as the index date. Patients 
who were not continuously enrolled with both medical and 
pharmacy beneﬁ  ts for at least six months prior to the index 
date (“baseline” period) and at least 30 days (or until date 
of death if patient died within the ﬁ  rst 30 days) following 
the index date (“follow-up” period) were excluded from the 
study sample.
Patients were considered to have been hospitalized for an 
upper GI bleeding event if they had at least one medical claim 
with any of the following International Classiﬁ  cation of 
Diseases, Ninth Revision, Clinical Modiﬁ  cation (ICD-9-CM) 
diagnosis codes listed in the primary position of an inpatient 
hospitalization (456.0, 456.20, 530.7, 530.82, 531.0x, 531.2x, 
531.4x, 531.6x, 532.0x, 532.2x, 532.4x, 532.6x, 533.0x, 
533.2x, 533.4x, 533.6x, 534.0x, 534.2x, 534.4x, 534.6x). 
In addition, other hemorrhages attributable to the GI tract: 
578.x or 459.0 (unspeciﬁ  ed hemorrhage) plus any upper GI 
diagnosis other than those appearing above, ie, 459.0 or 578.x 
plus any of [530.xx-537.xx, 558.x, 564.2-564.3] would clas-
sify a patient as having GI bleeding. For patients who had a 
GI bleeding event code listed above in a secondary position 
of an inpatient hospitalization AND the absence of a primary 
diagnosis code that would indicate a non-GI bleeding rea-
son for the hospitalization (eg, cardiac), a physician would 
review all primary diagnoses to verify the hospitalizations 
as for GI bleeding.
AMI study subject identiﬁ  cation
A second cohort of patients at least 18 years of age with 
evidence of an inpatient hospitalization for AMI during the 
period from January 1st, 2000 through December 31st, 2003 
was identiﬁ  ed from the claims data. These patients were 
selected for inclusion if they had not been hospitalized for 
AMI or for GI bleeding or for GI surgery in the six-month Clinical and Experimental Gastroenterology 2009:2 23
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pre-index period. The service date of the ﬁ  rst occurring 
hospitalization for AMI, without evidence of trauma, was 
deﬁ  ned as the index date. Hospitalizations for AMI were 
deﬁ  ned as any hospitalization where AMI is listed as the 
primary diagnosis code (ICD-9-CM code 410.xx).
To avoid situations where a patient had both GI bleeding 
and AMI during the initial inpatient stay, patients with both 
diagnoses during the initial hospitalization were removed 
from the study sample.
Matching
In this study, a critical task was to develop comparable 
cohorts of GI bleed and AMI patients. Because patients 
experiencing GI bleed and AMI patients may have different 
characteristics, matching was used to create two balanced 
cohorts. To create two balanced cohorts, the GI sample was 
matched to the corresponding AMI sample by hard-matching 
on year/quarter (eg, 2005 Q1) of study entry; age ± 2 years; 
gender; Charlson Comorbidity Index (CCI) score, and pro-
pensity score ± 0.01.
Propensity score model
The propensity score is the conditional probability of GI 
bleed given observed covariates. In a cohort study, matching 
the propensity score can be used to balance all of the observed 
covariates (which may be too numerous to independently 
hard-match on).17,18 For a given covariate pattern, the propen-
sity score is the predicted the probability of being a member 
of the GI bleed sample given a set of observed covariates. 
A logistic regression model was estimated to predict the prob-
ability of a hospitalization for GI bleed versus hospitalization 
for AMI for each patient. Factors considered for use in the 
propensity score model included patient demographics (age, 
gender), medication use, factors associated with mortality 
(eg, comorbid conditions), resource utilization and costs, 
and time of cohort entry (month/year).
Study measures
Variables used in matching
Patient demographic variables, age, gender, and geographic 
location were captured from the enrollment data. Age was 
deﬁ  ned as of the year of the index date. Filled prescriptions 
in the pre-index period were examined for medications of 
interest. Medications included were those associated with 
cardiovascular diseases (eg, ACE inhibitors, angiotensin 
receptor blockers [ARBs], beta-blockers, alpha-blockers, 
calcium channel blockers [CCBs], nitrates, and lipid-lowering 
agents) as well as those that were associated with GI disorders 
(eg, H2 blockers, NSAIDs, and proton pump inhibitors). 
Comorbidities, an important confounding factor, were mea-
sured during the baseline period using the CCI,19,20 a clinical 
index that incorporates 19 categories of comorbidity which 
are primarily deﬁ  ned using ICD-9-CM diagnoses codes 
(a few procedure codes are also employed). Each category 
is assigned a weight to indicate relative comorbidity, which 
is based on the adjusted risk of one-year mortality. Patients’ 
CCI score is the weighted sum of the conditions. The overall 
comorbidity score reﬂ  ects the cumulative increased likeli-
hood of one-year mortality; the higher the score, the more 
severe the burden of comorbidity. Table 1 presents the base-
line CCI components.
Outcome variables
The main outcome variable evaluated in this study was 
mortality during initial hospitalization and mortality after 
discharge from the initial hospitalization thru 30-, 60-, and 
90-days. The National Death Index (NDI) database was used 
to compile mortality information. The NDI is a computer-
ized list of death records in the US compiled by the National 
Center for Health Statistics through contractual agreements 
with state vital statistics ofﬁ  ces. The database includes deaths 
reported since 1979 and is updated with approximately two 
million deaths annually from all 50 US states, the District of 
Columbia, Puerto Rico, and the Virgin Islands. All data for a 
given calendar year are added to the NDI approximately one 
year later. At the time of this study, the NDI death records 
were complete through the end of 2005. NDI users submit 
information on as many as 12 potential matching variables, 
from which returned records are ranked on the basis of a 
probabilistic scoring mechanism to determine the likelihood 
of a true match. The user then must decide which NDI records 
may be associated with the subjects in question.21
Procedures and rehospitalizations were also evaluated 
30 days following the index date. Inpatient and outpatient 
claims were used to identify cardiac revascularization for 
the AMI sample and GI endoscopy for the GI bleed sample. 
GI endoscopy was chosen as patients are likely to undergo 
an endoscopy to follow up on a lesion or if re-bleeding is 
suspected. Cardiac revascularization was chosen as many 
patients following an AMI have coronary disease requir-
ing subsequent revascularization by either stent or surgery. 
In addition, pre-index health care costs from medical and 
pharmacy claims for services delivered in the six-month 
pre-index period were calculated as a function of health plan 
and patient liability. Reported costs reﬂ  ect the total amounts 
paid by the health plan and the patient.Clinical and Experimental Gastroenterology 2009:2 24
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Analysis
The study outcomes (mortality, rehospitalization, and select 
procedures) were compared between the matched cohorts 
using a Chi-squared test. Comparison of all continuous 
variables was based on two-sample t-tests and Chi-squared 
test for dichotomous variables. All analyses were conducted 
using the SAS software program (version 9.0; SAS Institute, 
Inc., Cary, NC, USA). Matching and propensity score models 
were performed using Stata statistical software (version 9.0; 
Stata Corporation, College Station, TX, USA).
Results
Patient characteristics
A total of 12,437 patients met the study criteria for inclusion 
into the GI bleed sample and 22,847 for inclusion into the 
AMI sample. Prior to matching, patients in the GI bleed and 
AMI samples differed signiﬁ  cantly with regard to patient 
characteristics, medication use, CCI score, and health care 
utilization and costs, as shown in Tables 2 and 3. Patients 
in the AMI sample were generally older, and a signiﬁ  cantly 
higher proportion of the AMI cohort was male. A comparison 
of baseline medication use revealed several signiﬁ  cant differ-
ences between the cohorts. Patients in the AMI sample were 
signiﬁ  cantly more likely to have taken most cardiovascular 
medications, including ACE inhibitors, ARBs, beta-blockers, 
alpha-blockers, CCBs, nitrates, and lipid-lowering agents. By 
contrast, patients in the GI bleed sample had higher use of both 
GI medications (ie, proton pump inhibitors, H2 antagonists, 
and sucralfate) and medications known to increase risk for GI 
bleeding (ie, anticoagulants, corticosteroids, bisphosphonates, 
COX-2 inhibitors, and other NSAIDs). The GI bleed sample 
also had a higher mean CCI score than the AMI sample. 
Similarly, a comparison of baseline utilization and costs by 
patients in each sample found that the GI bleed sample had 
signiﬁ  cantly higher values on nearly every measure. Figure 1 
reports prematch mortality outcomes.
Following the matching procedure, 6,923 matched pairs 
were identiﬁ  ed and included in the analytic dataset. The 
goal of the matching process was to create two cohorts that 
were balanced on observable demographics and clinical 
characteristics. After matching, demographic and clinical 
characteristics of the GI bleed and AMI cohorts appeared 
very similar (Tables 2 and 3). Despite a relatively large 
sample size, formal statistical tests showed no evidence of 
statistically signiﬁ  cant differences between cohorts. Of note, 
baseline medication use was not factored into the propensity 
score model because many medications were found to be 
too strongly correlated with the cohort. Clinically, this is a 
reasonable assumption as one would expect differential use 
of speciﬁ  c medications between cohorts (eg, use of nitrates 
is more than two times greater in the AMI cohort while H2 
antagonists are more commonly used among the GI bleed 
patients). Emergency room (ER) costs were the only expen-
ditures that differed between the GI bleed and AMI cohorts 
Table 1 Pre-match: baseline Charlson Comorbidity Index components
Variables GI bleed N = 12,437 AMI N = 22,847 p-value
AIDS 264 (2.12%) 384 (1.68%) 0.2315
Hemiplegia or paraplegia 92 (0.74%) 76 (0.33%) 0.0002
Cerebrovascular disease 533 (4.29%) 876 (3.83%) 0.0386
Diabetes with chronic complications 690 (5.55%) 1,450 (6.35%) 0.0367
Mild or moderate diabetes 1,464 (11.77%) 3,498 (15.31%) 0.0001
Moderate or severe liver disease 492 (3.96%) 39 (0.17%) 0.0001
Mild liver disease 251 (2.02%) 38 (0.17%) 0.0001
Metastatic solid tumor 1,446 (11.63%) 942 (4.12%) 0.0001
Any malignancy 1,384 (11.13%) 1,576 (6.90%) 0.0001
Congestive heart failure 630 (5.07%) 1,255 (5.49%) 0.0880
Dementia 60 (0.48%) 63 (0.28%) 0.0017
Myocardial infarction 131 (1.05%) 2,815 (12.32%) 0.0001
Peptic ulcer disease 547 (4.40%) 112 (0.49%) 0.0001
Chronic pulmonary disease 1,490 (11.98%) 2,187 (9.57%) 0.0001
Peripheral vascular disease 365 (2.93%) 661 (2.89%) 0.8240
Renal disease 660 (5.31%) 882 (3.86%) 0.0001
Rheumatologic disease 281 (2.26%) 328 (1.44%) 0.0001Clinical and Experimental Gastroenterology 2009:2 25
Mortality associated with gastrointestinal bleeding
in the health care costs/utilization category after matching 
during the six-month period prior to the index date: lower 
ER costs were seen in the GI bleed cohort ($102 vs $130; 
p = 0.002). Total health care, medical, and pharmacy costs 
were all similar during the baseline period (Table 3).
Post-matched outcomes
The overall 30-, 60-, and 90-day mortality rates for the GI cohort 
were 2.54%, 3.12%, and 3.42%, respectively. These overall 
mortality rates were lower than the corresponding mortality 
rates of the matched cohort of AMI patients (4.35%, 4.78%, 
and 5.06%, respectively), as shown in Figure 2. The majority of 
the difference in overall 30-day mortality between GI bleed and 
AMI patients (2.54% vs 4.35%) was accounted for by mortality 
during the initial hospital stay (1.91% vs 3.58%). The 30-day 
mortality excluding those within the initial hospitalization 
did not differ between the cohorts (0.64% vs 0.77%). When 
mortality during the initial hospitalization was removed from 
the 60- and 90-day mortality rates, results between cohorts were 
similar. The “adjusted” 60-day mortality rates in the GI bleed 
and AMI cohorts were 1.21% and 1.20%, respectively, while 
the 90-day rates were 1.52% and 1.47%, respectively.
Table 2 Pre-match and post-match: Patient characteristics
Variables Pre-match cohort Post-match cohort
 GI  bleed
N = 12,437
AMI
N = 22,847
p-value GI bleed
N = 6,923
AMI
N = 6,923
p-value
Age
Mean age (SD) 53.83 (14.88) 56.51 (11.27) 0.0001 55.41 (12.03) 55.38 (12.00) 0.8981
Age 18–34 1,305 (10.49%) 422 (1.85%) 0.0001 226 (3.26%) 219 (3.16%) 0.7359
Age 35–64 8,475 (68.14%) 17,999 (78.78%) 0.0001 5,429 (78.42%) 5,466 (78.95%) 0.4426
Age 65+ 2,657 (21.36%) 4,426 (19.37%) 0.0001 1,268 (18.32%) 1,238 (17.88%) 0.5078
Gender
Female 5,352 (43.03%) 6,091 (26.66%) 0.0001 2,224 (32.12%) 2,224 (32.12%) 1.0000
Male 7,085 (56.97%) 16,756 (73.34%) 0.0001 4,699 (67.88%) 4,699 (67.88%) 1.0000
Mean Charlson
score (SD)
0.86 (1.47) 0.74 (1.24) 0.0001 0.46 (0.82) 0.46 (0.82) 1.0000
Table 3 Pre-match and post-match health care costs and utilization
Variables Pre-match cohort Post-match cohort
GI bleed
mean (Std)
N = 12,437
AMI
mean (Std)
N = 22,847
p-value GI bleed
mean (Std)
N = 6,923
AMI
mean (Std)
N = 6,923
p-value
Costs ($)
Total cost 4,018.53 (10,464.16) 2,847.08 (7,210.41) 0.0001 2,116.93 (4,801.37) 2,170.10 (4,381.95) 0.4962
Medical cost 3,146.64 (10,011.78) 2,153.53 (6,879.02) 0.0001 1,501.35 (4,566.19) 1,551.75 (4,145.41) 0.4965
Outpatient cost 2,055.80 (6,462.97) 1,322.27 (4,855.34) 0.0001 907.52 (2,276.14) 916.54 (2,098.91) 0.8084
ER cost 145.57 (531.11) 153.26 (764.16) 0.2683 101.64 (405.05) 130.06 (658.97) 0.0022
Inpatient cost 697.48 (5,891.03) 491.68 (3,585.03) 0.0004 365.21 (3,382.25) 358.57 (2,744.51) 0.8991
RX cost 871.88 (1,514.25) 693.56 (1,255.46) 0.0001 615.58 (1,023.79) 618.34 (1,008.01) 0.8729
Utilization (# of 
visits per patient 
per year)
Inpatient visits 0.08 (0.330) 0.06 (0.270) 0.0001 0.04 (0.24) 0.04 (0.23) 0.6868
Outpatient visits 3.07 (6.40) 1.96 (4.62) 0.0001 1.55 (2.66) 1.49 (2.63) 0.1608
Ofﬁ  ce visits 5.75 (7.29) 4.17 (5.90) 0.0001 3.56 (4.00) 3.61 (4.11) 0.4123
ER visits 0.35 (1.03) 0.25 (0.81) 0.0001 0.23 (0.61) 0.22 (0.62) 0.3928Clinical and Experimental Gastroenterology 2009:2 26
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Age was also found to be an important variable in patient 
mortality in both cohorts of patients. A stratiﬁ  cation of 
mortality by age found that the mortality rate increased with 
every decade of a patient’s age. For the GI bleed population, 
30-day mortality for patients under age 35 was 0%–2% and 
increased to close to 6% in patients 75 years and older. With 
the exception of patients 18–24 years of age, similar trends 
were observed for the AMI cohort. Figure 3 shows the 90-day 
mortality stratiﬁ  ed by age.
A comparison in the rate of change of mortality over 
time between the GI bleed and AMI cohorts demonstrated 
a faster growth rate in the GI bleed cohort. Mortality due to 
GI bleed increased by 35% between day 30 and day 90 post-
index date (absolute value = 0.88%), while the AMI group 
saw a 16% mortality increase during the same time period 
(absolute value = 0.71%).
A comparison of procedures and rehospitalizations 
among the matched cohorts found that AMI patients had 
higher rates of rehospitalization (2.56% vs 1.79%; p = 0.002), 
while GI bleed patients were more likely to have a procedure 
within 30 days following their initial hospitalization admis-
sion (72.38% vs 44.95%; p  0.001) (Figure 4).
Discussion
The main objective of this analysis was to compare the 
short-term clinical outcomes of an upper GI bleeding event 
with those of an AMI. To that end, we identiﬁ  ed samples of 
individuals with a GI bleeding event or an AMI and matched 
them to each other on a number of speciﬁ  c patient charac-
teristics and their propensity scores.
Prior to matching, the GI bleed sample had a higher mean 
CCI score than the AMI sample. Similarly, a comparison of 
baseline utilization and costs by patients in each sample found 
that the GI bleed sample had signiﬁ  cantly higher values on 
nearly every measure. These results may suggest that patients 
in the GI bleed sample had a higher burden of disease than 
did those in the AMI sample, which is not what would be 
expected. Alternatively, it is possible that the higher propor-
tion of females in the GI bleed sample may have driven this 
difference, as females are known to utilize health care at a 
greater level than males.22
Patients in the GI bleed and AMI samples were matched 
to one another to create two cohorts that were balanced on 
observable demographics and baseline characteristics. After 
matching, the resultant GI bleed and AMI cohorts each 
included 6,923 patients. The cohorts did not differ with regard 
to age or gender. However, many differences with regard 
to medication use remained because we did not match on 
these as the medication used by the patients would not alter 
the mortality rate. The matched cohorts were found to have 
similar CCI scores and to be similar on nearly all utilization 
and cost measures (excepting ER costs). Of note is that the 
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matched cohorts appeared to have lower CCI scores, as well 
as lower utilization rates and incurred costs, compared with 
the initial GI bleed and AMI samples. It appears, therefore, 
that patients in the matched cohorts had lower disease burden 
than the underlying GI bleed and AMI patient populations. 
It is possible that the magnitude of the study outcomes (eg, 
mortality) will be underestimated as a result, although the 
comparison of the GI bleed and AMI cohorts should still 
be valid.
A comparison of outcomes among the matched cohorts 
found that AMI patients had higher rates of mortality and 
rehospitalization, while GI bleed patients were more likely 
to have a procedure following their initial hospital admis-
sion. A closer examination of the 30-day mortality for the 
study cohorts found that the majority of the difference in 
overall 30-day mortality between GI bleed and AMI patients 
(2.54% vs 4.35%) was accounted for by mortality during the 
initial hospital stay. Once mortality during the initial hospital-
ization was removed from the 60- and 90-day mortality rates, 
we found similar results. This may be expected, as the cohorts 
were matched on a number of characteristics, including CCI 
score, a validated measure for predicting mortality.
We found mortality among hospitalized AMI patients 
to be signiﬁ  cantly lower than in the published literature. 
Rasmussen and colleagues15 estimated AMI mortality 30 days 
after hospital admission to be 7% for 30- to 64-year-olds 
and 15.9% for 65- to 74-year-olds. The current study found 
30-day mortality to be 4.85% among unmatched AMI 
patients and 4.35% among matched AMI patients. A number 
of reasons may help explain the difference in 30-day 
mortality. First, the populations differ in that the current study 
examines US managed care enrollees, while the Rasmussen 
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study uses Denmark’s National Patient Registry containing 
administrative data for hospitalizations. A closer look at the 
Rasmussen study reveals that among the 30- to 64-year-old 
AMI patients, mortality of high- and medium-income level 
patients was 5.1% and 6.5%, respectively.15 Presumably, the 
current study’s population would be skewed toward an under 
65 age group with moderate to high incomes. Although not 
conclusive,23,24 there is considerable evidence that, at least 
within the United States, income inequality is associated 
with poorer population health.25–27 More speciﬁ  cally, the 
relationship between income inequality and mortality has 
also come into question in many studies and many have 
concluded that income inequality remained a signiﬁ  cant 
correlate of mortality, particularly in the United States.28–31 
An examination of the current study’s mortality by age strata 
illustrates that mortality does increase with age, but this 
increase may be tempered by the income effect. Furthermore, 
the Rasmussen study data are from 1995–2002, whereas the 
current study examines AMI patients during the period from 
2000–2003. As treatment options have evolved, mortality 
may be decreasing, if only slightly.
Mortality rates among hospitalized upper GI bleed patients 
also appear lower than estimates found in the literature. Thirty-
day mortality rates for GI bleeding have been reported to be 
between 5% and 15% (the lower rates being for patients under 
65 years of age).32–36 The current study found lower 30-day 
mortality (3.54% among unmatched patients and 2.54% 
among matched patients). Christensen and colleagues37 esti-
mated 30-day mortality to be 4.3% in an under 65 population, 
10.2% in those aged 65–79, and 17.0% in those aged 80+. 
However, Christensen examined only 30-day mortality after 
peptic ulcer bleeding, whereas the current study uses a much 
broader deﬁ  nition of upper GI bleed, encompassing some 
patients who may have a lower risk of mortality. An examina-
tion of mortality by age strata reveals that although mortality 
increases with age in our study, this increase may be tempered 
by the inclusion of other types of GI bleed (besides peptic 
ulcer). Yavorski and colleagues10 conducted a retrospective 
study that evaluated 3,294 cases of upper GI bleeding in US 
military medical facilities. The mean age of the population was 
52 years, which was similar to the mean age of the matched 
population in our study of 55 years. The overall mortality 
rate was 7.0% and also slightly lower than in most previous 
studies.10 The mortality rate observed in this and other studies 
reporting lower mortality rates may be more reﬂ  ective of the 
average mortality in the community at large.10
Mortality also varies depending upon the cause of the 
bleeding. Wilcox and colleagues9 prospectively evaluated 
796 patients from the gastroenterology consultative service at 
a large inner-city hospital over a 50-month period. Although 
the overall mortality rate was 8.8%, signiﬁ  cant differences 
were detected according to the cause of bleeding. The mor-
tality was 2.4% among patients with Mallory–Weiss tear 
and 4.3% among those with peptic ulcer bleeding, including 
gastric ulcer (4.2%) and duodenal ulcer (4.3%). By contrast, 
the mortality associated with portal hypertension-related 
bleeding was 32% (esophageal varices, 32%; gastric varices, 
50%; portal hypertensive gastropathy, 23%).9 Our study 
also evaluated patients with upper GI bleeds due to a broad 
number of causes, some of which are associated with lower 
rates of mortality. When evaluating the cause of the GI bleed 
hospitalization in our study, we found that our study popula-
tion had a low number of hospitalizations caused by variceal 
bleeding, a condition that is usually associated with a high 
mortality rate. In our study, only 4.62% of the hospitalizations 
were due to variceal bleeding in the matched cohort. This 
further explains the lower mortality rate seen in this study 
as compared with some other published studies.
Limitations
While claims data are extremely valuable for the efﬁ  cient 
and effective examination of health care outcomes, treat-
ment patterns, health care resource utilization and costs, 
claims data are collected for the purpose of payment and not 
research. Therefore, there are certain limitations associated 
with the use of claims data. First, presence of a claim for a 
ﬁ  lled prescription does not indicate that the medication was 
consumed, nor does it indicate that it was taken as prescribed. 
Second, medications ﬁ  lled over-the-counter or provided 
as samples by the physician will not be observed in the claims 
data. Third, presence of a diagnosis code on a medical claim is 
not positive proof of the presence of disease, as the diagnosis 
may be incorrectly coded or included as a rule-out criterion 
rather than representing actual disease.
Conclusion
GI bleeding events result in signiﬁ  cant mortality similar to 
that of an AMI after adjusting for the initial hospitalization. 
In this study, we identiﬁ  ed a lower overall mortality among 
patients with upper GI bleeding compared to other published 
studies. This favorable mortality could be a reﬂ  ection of the 
average mortality in the community at large. It could also be 
due to improved techniques of diagnosis and more frequent 
use of effective endoscopic therapy in this patient popula-
tion. This research can help physicians weigh the risks of GI 
bleeding against the beneﬁ  ts of therapies that may contribute Clinical and Experimental Gastroenterology 2009:2 30
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to GI bleeds. Future study will need to evaluate the cost 
and resource utilization associated with GI bleeding events 
leading to mortality.
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